QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

MiMedx Group Stock Price, News & Analysis (NASDAQ:MDXG)

$7.89
-0.03 (-0.38%)
(As of 11/28/2023 ET)
Compare
Today's Range
$7.73
$7.94
50-Day Range
$5.70
$7.92
52-Week Range
$2.43
$8.60
Volume
612,935 shs
Average Volume
671,642 shs
Market Capitalization
$918.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.9% Upside
$11.67 Price Target
Short Interest
Healthy
3.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of MiMedx Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$35,800 Bought Last Quarter
Proj. Earnings Growth
277.78%
From $0.09 to $0.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

162nd out of 949 stocks

Surgical & Medical Instruments Industry

22nd out of 95 stocks


MDXG stock logo

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

MDXG Stock News Headlines

MiMedx Group Inc MDXG
MiMedx Group (NASDAQ:MDXG) Shares Up 5.4%
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX to Highlight Published Data at SAWC Fall
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Q3 2023 MiMedx Group Inc Earnings Call
MiMedx Group Q3 Earnings Preview
Unraveling MiMedx's Surgical Precision In Growth
MIMEDX Announces Launch of EPIEFFECT™
MDXG: Beat and a Raise
Q2 2023 MiMedx Group Inc Earnings Call
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXG
Employees
867
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$12.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+47.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-30,200,000.00
Pretax Margin
1.60%

Debt

Sales & Book Value

Annual Sales
$267.84 million
Book Value
($0.16) per share

Miscellaneous

Free Float
93,218,000
Market Cap
$918.24 million
Optionable
Optionable
Beta
1.63
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. William F. Hulse IV (Age 49)
    General Counsel & Chief Administrative Officer
    Comp: $677.36k
  • Dr. Robert Benjamin Stein M.D. (Age 72)
    Ph.D., President of Regenerative Medicine & Biologics Innovation
    Comp: $639.28k
  • Mr. Joseph H. Capper (Age 59)
    CEO & Director
  • Mr. Douglas C. Rice CPA (Age 57)
    Chief Financial Officer
  • Mr. Scott M. Turner (Age 57)
    Senior Vice President of Operations & Procurement
    Comp: $493.98k
  • Mr. Matthew M. Notarianni
    Head of Investor Relations
  • Mr. Mark P. Graves (Age 57)
    Senior VP & Chief Compliance Officer
  • Hilary Dixon
    Vice President of Investor Relations & Corporate Strategic Communications
  • Ms. Kate Surdez
    Chief Human Resources Officer
  • Dr. David H. Mason Jr. (Age 76)
    Chief Medical Officer














MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price target for 2024?

3 Wall Street analysts have issued 1 year target prices for MiMedx Group's stock. Their MDXG share price targets range from $11.00 to $12.00. On average, they expect the company's share price to reach $11.67 in the next year. This suggests a possible upside of 47.9% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2023?

MiMedx Group's stock was trading at $2.78 on January 1st, 2023. Since then, MDXG stock has increased by 183.8% and is now trading at $7.89.
View the best growth stocks for 2023 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MDXG earnings forecast
.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) announced its earnings results on Monday, October, 30th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. The business earned $81.71 million during the quarter, compared to the consensus estimate of $76.69 million.

What ETF holds MiMedx Group's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include Cannell Capital LLC (1.95%), Richmond Brothers Inc. (1.27%), Charles Schwab Investment Management Inc. (0.92%), Northern Trust Corp (0.92%), Federated Hermes Inc. (0.72%) and Royal Bank of Canada (0.71%). Insiders that own company stock include Mark Graves, Peter M Carlson, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends
.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -